Ladies and gentlemen, thank you for standing by and welcome to the AngioDynamics fiscal second quarter 2010 conference call. (Operator Instructions) This conference is being recorded today, Tuesday, January 5 of 2010 and I would now like to turn the conference over to Doug Sherk. Please go ahead, sir.

Thank you for joining us this afternoon for the AngioDynamics conference call to review the results for the fiscal second quarter of 2010 which ended on November 30, 2009. The news release announcing the second quarter earnings crossed the wire this afternoon after the market closed and is available on the AngioDynamics website. We’ve arranged for a recording of this call which may be accessed by phone. The replay will become available at approximately 6:30 PM Eastern Time this evening and will remain available for seven days. The operator will provide the dial in information at the conclusion of today’s call. In addition, the call is being broadcast live on the web at http://investors.AngioDynamics.com. A replay of the call will also be available of this webcast. Before we get started, during the course of this conference call the company will make projections or forward-looking statements regarding future events including the statements about revenue and earnings for fiscal 2010. We encourage you to review the company’s past and future filings with the SEC, including without limitation the company’s Forms 10-Q and 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in forward-looking statements. In addition, today’s presentation includes certain financial measures used to better understand our business that have not been prepared in accordance with the generally accepted accounting principles better known as GAAP. An explanation and reconciliation of these non-GAAP measures has been provided in today’s news release issued by the company and is available on the company’s website. AngioDynamics uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends of the company’s business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, financial reporting measures prepared in accordance with GAAP. In today’s call the company has reported non-GAAP EBITDA and EBITDA per share and has reviewed these measures as an internal analysis and review of operational performance. Finally, during the question-and-answer period today we’d like to request each caller to limit themselves to two questions and encourage callers to re-queue to ask additional questions. We appreciate everyone’s appreciation with this procedure. And now I’d like to turn the call over to Johannes Keltjens, President and Chief Executive Officer of AngioDynamics.

Thanks, Doug, and good afternoon everyone. Thank you for joining us for our second quarter conference call and with me here today is Joe Gersuk, our CFO. We followed up our good start to the fiscal year with a solid second quarter. Net sales grew 10% from prior year and for the first half of the fiscal year net sales were up 12%. Our second quarter was driven by strong growth from our Oncology/Surgery business and good control of our operating expenses. These factors offset a decline in gross margin. What is especially encouraging is that our growth was broad based with a majority of our product lines contributing. And we believe our growth appears to be more rapid than the overall market we operate in. Our results can be directly attributed to the diverse strength of our company and its business model, which relies heavily on disposable products used in non-elective procedures. All of our Oncology/Surgery product lines grew during the quarter, yielding a strong 28% overall growth. LC Beads and the Habib Radio Frequency Knife continued to show particularly rapid growth, with increased sales also coming from RF oblation. We were very pleased with the growth in net sales of the NanoKnife IRE System. NanoKnife generated $700,000 in revenue in the fiscal second quarter. To date, physicians have treated a total of 104 patients in nine centers around the world, utilizing the NanoKnife IRE System. This represents an additional 18 patients since the last call in early October. Procedures now have been performed on seven different organs, specifically prostate, liver, lung, kidney, lymph nodes, bone, as well as pancreas. And we are particularly pleased to see that the NanoKnife has been used for the first time to treat a tumor in the pancreas. This patient was treated now…

Thank you, Johannes, and good afternoon ladies and gentlemen. Today we are reporting second fiscal quarter sales growth of 10% to $53.5 million. Our strong growth this quarter was again led by our Oncology/Surgery unit, which reported $13.6 million in sales and achieved a record quarterly growth rate of 28%. The sales growth was led by strong sales of LCDs as well as $700,000 in IRE NanoKnife sales. The IRE NanoKnife sales program initiated this quarter offers prospective commercial sites either a lower price generator for purchase outright or a probe generator bundle commitment, under which the generator is purchased over a two year period. A total of seven hospitals committed to the program in the second quarter, all of which are in the U.S. Our goals with this new program are twofold, to generate revenues and develop a group of commercial sites that make a commitment to use NanoKnife in their clinical practice. And we are obviously very pleased with the initial market response to this program. Peripheral Vascular business unit sales grew 6% in the quarter to $23.2 million, and as you know we’ve provided laser ablation sales data for the first year following the acquisition of Diomed. However, this level of detail impacts our competitive position in the market. In addition, as you are aware our largest competitor in the vein ablation market was recently acquired and no longer provides sales information. Therefore, we have elected to discontinue providing specific laser ablation sales data with the issuance of our fiscal second quarter results. We enjoyed a strong quarter with our new Renal Infusion System, posting $832,000 in sales as a benefit TRT product. Access business unit sales grew 4% in the quarter to $16.7 million. In the very price competitive markets for PICCs, ports and dialysis products,…

Thank you. (Operator Instructions) Your first question comes from Seth Damergy - Deutsche Bank.

First I just wanted to touch on the margin a little bit and see if you can kind of hash out the pricing pressure that you talked about. I guess it seems like it’s isolated to the port and PICC business. Is that so? Is it across the board or are you just seeing it in specific like large institutions?

Well, I think what we are seeing is not unique in the industry. I think we’re picking up similar comments from our colleagues in the marketplace. I think in our case I think the dimension I would add to that, so I think the pressure’s indeed confined to the Access business I’d say, so dialysis, ports and PICCs. Not every single product in that area has the same pressures, but I think it would go into too much detail to tell you in all detail what’s happening to individual products. But the other thing that’s happening here is we are growing revenue and certainly also units in all three product lines, and I think what we are growing is also we are very much in the corporate accounts area, where the average selling price or the incremental business is below our historical average. And that pushes down the average selling price of all our product lines. So part of it is also math. It’s not necessarily that existing customers go down in price as such, unless of course they come off contract and we have to renegotiate a new contract. So part of it we think is also a result of our growth and part of it is some of the premium prices of some of the newer product lines are coming down a little bit. Nothing alarming. I don’t think we’re losing more than anybody else, but certainly part of the reason why we have to report a drop in gross margins.

And then with your new product launches, I mean you’ve talked about a number of them and I’m sure over the coming months there’s a significant amount of new products to come along, will that help your margin in the future I guess pick up a bit or I guess will that help your margin?

Well, a product like NanoKnife and Benephit, by the way, that kind of highly [novative] products are significantly above the average margin. One, Joe and I also mentioned mix in terms of headwind as for instance a product like LC Bead, which continues to grow very, very healthy but has below average margins. But I think you also heard us saying that we very much focus on running the business on operating income, whereas a product like LC Bead has below average margin, the overall profitability of the product line is actually very good. So in the mix it kind of works out.

Your next question comes from Brooks West - Craig-Hallum Capital.

Joe, I understand why you don’t want to break out EVLT sales any more, but are you comfortable with the statement that you’re still growing kind of at or above market, where you were last quarter?

We probably grew a bit less than the market last quarter, and had a very strong quarter last year in the second quarter and so we think it is more an issue of a difficult comparison to the prior year. But as we noted, we did have great strong sales of the disposable kits in this second quarter.

And then Johannes, on the international opportunity, can you frame that a bit better? Do you see specific product opportunities, you know, maybe more on the Peripheral side versus the Access side? And should we look for your international revenues to grow at a pace higher than the U.S.?

Well, it’s certainly the aspiration without saying it’s going to happen tomorrow morning, but it’s certainly the aspiration. I don’t want to set up Stephen McGill for failure here, either. He’s building his team. But obviously the international market is huge and I think what we would consider in the U.S. as our flagship products we want to turn into global growth franchises. So obviously Oncology. We see tremendous opportunities outside U.S., particularly in Asia Pacific but also in Western Europe. And we’re certainly under developed in those markets compared to our market position in the U.S. I think frankly the Access business has a lot of opportunities, just slightly different rules to the game over there than here in the U.S. And the EVLT business is one of our stronger franchises, also international, continues to show good growth and we think we can drive that further. And on the heels of that, some of the other Peripheral products. But I’d say for all intents and purposes, international Oncology, the Vein Intervention business and the Access business are probably going to be the horses we’re going to ride initially international.

Your next question comes from Jayson Bedford - Raymond James.

First, on the cost side you did leverage the operating line nicely, at least sequentially, and I’m wondering is it a timing issue or is this kind of a level of OpEx that we should expect going forward?

No, it’s not necessarily the level we should expect going forward, if you suggest, it would be flat so it will certainly rise as sales rise through the balance of the year. But we felt that gross margin issue for a while and have made some adjustments on the cost side of the business. Our headcount in the company has not changed significantly from the beginning of the year, when you account for some temporary people that we had previously. So the fulltime headcount has not changed at all over the six month period of time, and we’ve reduced certain marketing expenditures and controlled G&A costs as well. So have had a strong program to control the costs for a number of months and we’ll continue to have the brakes on on all non-essential spending on the operating side, well, for the foreseeable future until things improve on the gross margin side.

On NanoKnife, the $700,000 in the quarter, is this kind of a bolus or you know with respect to the new program? Or is this a level that you would expect going forward, the $700,000?

Well I think we said, and Jayson by the way, thanks for reminding us it is Happy New Year to everybody on the call. I should have opened up with that. I think I said a quarter ago or so that revenues will go up and down a little bit and it’s a little hard to predict for us because there’s a capital component in there that’s sometimes complex formulas for revenue recognition, and that’s why in addition to our revenue number we’re also disclosing the number of centers that are using the system, the number of new sites that have been opened up, which were seven in the last quarter, and the number of patients that have been treated. We think the $700,000 level is something. We wouldn’t be surprised if we see something like that again or a little more, but also could be a little less. And sometimes a little hard to predict for when that exactly falls. But the underlying trend is there and we think it’s not a fluke that we had a, you know, very pleasant quarter on the revenue side in NanoKnife. Maybe also to add to this, Jayson, that these centers not all of them are operational yet, and some of them have to yet be trained and start doing procedures. I think that will drive the momentum also forward.

Your next question comes from Gregory Brash - Sidoti & Company. Gregory Brash - Sidoti & Company: On the Access side, Joe, you mentioned some pricing pressure and so did your competitor. Your competitor also mentioned you know they may be losing market share, specifically on the port side. Is that where you’re seeing the gains? Is it more on the ports and the PICCs?

Well, to a point it’s reading the tea leaves and whose market estimates you believe, but if we add up all the market estimates and divide them by the number of contributors, we actually may be gaining share. I think we’re certainly gaining share in dialysis and we may well be gaining share both in ports and PICCs in the quarter. So, you know, the underlying trend is not bad, but some of the glamour, some of the shine of course is taken off by the price erosion. But the unit growths are good and again assuming those market estimates, we may be gaining share. I would certainly believe that. Gregory Brash - Sidoti & Company: Are some of those market share gains and some of the price erosion, you being more willing to go down to a lower price? Or are you, you know, holding what [you] can and it’s just that the market’s dictating that?

Well, it’s an [end] I think to this whole thing. You know we’re in the ball game so we’re playing ball, but we’re certainly not a price aggressor. I want to be very clear on that. I don’t think we are. It’s hard to say. But that’s not where we’re coming from. We’re trying to sell value. Somebody on the call mentioned earlier the new website that went up on EVLT, I think, is a great example on what kind of support we provide to our customers to just enhance the value of doing business with AngioDynamics. And we’re trying to do the same thing in other parts of our business, whether that’s a training program for physicians and nurses and all that. But at the end of the day we’re in the game, we have a very strong strategic drive to increase our share and increase the volumes, because we believe it’s a key driver for, you know, keeping the business healthy and allowing us to drive gross margins up, so yes, we will engage in the battle and we are competitive if we need to be, but we’re not a price aggressor. Gregory Brash - Sidoti & Company: And then on the NanoKnife side, you know, that was really the big surprise here in this quarter. Can you remind us what you did last quarter with NanoKnife and what you think ultimately drove that improvement? Do you think a lot of that was the new program or is there just, you know, enough data out there that physicians are starting to get comfortable with the product?

Well, we had $42,000 in sales last quarter and we would really attribute all of the performance this quarter to this new program and kudos to our guys in the business unit who thought it up and have driven it and sold it to Johannes. And it’s been a great response on the lower price generators was one program and in fact the majority of the revenue is generator sales. And the alternative program is a commitment to a bundle of probes and the generator by which the generator is essentially purchased over a two year period of time. And as Johannes mentioned, most of these sites have just started, you know, getting the generator installed. So we have some optimism that there should be a good stream of revenue coming out of these seven centers, you know, going forward, as Johannes mentioned.

If I can add to that, Joe, also I think there’s a correlation between how sophisticated our team is and the track we have in the marketplace. I think it’s fair to say that the vast majority of the revenue we report in the second fiscal quarter came from the U.S., where we clearly have the strongest organization. I don’t want to take anything away from our international people, but we just don’t have that clinical expertise, that engineering support yet. Stephen McGill is aggressively building that team and we think that we can start showing revenue international hopefully in the not too distant future as well. But apart from that commercial effort, that positioning and that training program, I think there’s ongoing cases being done and as I tried to comment in my remarks, the safety profile is just very strong. I think that word is getting out there, the anecdotal result, also the way we share them sometimes at [symposia] and the way physicians share them amongst each other gets out there a little bit, and that word gets out there a little bit and starts getting some confidence in the marketplace as such. Gregory Brash - Sidoti & Company: You’re reducing your gross margin due to just some of the pressures you’re seeing on price. I’m curious, are you still on track? You know, pricing pressure aside, improving margins by moving some more of the production in house. I know you’re looking for some pretty decent improvement in the second half of this year. Is that still on track?

Yes, I was with you all the way until you said decent improvement in the back half of the year. I think we’re on track, but I think we said before some of the measures we are taking, you know, for instance hinge on product launches and it just takes a little bit of time to get those products out there, ramp up the volumes and all that. But I’d say we have no major setbacks in those programs. You know we do notice and I think some of our colleagues have commented on that as well. If we change a product or move a location that requires a filing, it takes a little more time than it used to take. You know things like a special [inaudible] in the past is of no practical value any more nowadays, but no fundamental setbacks from that point of view, Greg.

Your next question comes from [Unidentified Analyst] for Jason Mills - Canaccord Adams. [Unidentified Analyst] for Jason Mills - Canaccord Adams: My first question is on international expansion plans. Can you give a little bit more color on plans there, for example, how many [OUS] direct reps do you have now and have you thought about what the good number going forward?

Well, you know, I was trained in a certain school that’s best summarized saying pay as you go. The Oncology business is directly in three countries, the UK, France and Germany and between those three countries I want to say we’ve probably got about 12 sales reps. Something along those lines. I think you will see that inching up. And then you know as revenues go up, as we develop our plans, we’ll hire the people to go along with that. But I think we said before, and I know we don’t break out a separate international P&L, but we don’t expect a significant you know investment overnight in that business. It’s more going to be a gradual uptick of our infrastructure while revenue grows, while business grows and such.

And a substantial part of our international revenue comes through our distributors. We have a wide international network of distributors. And we do see particular growth opportunities in the Asia Pacific region, where we’re starting to get some real traction in China as an example.

I’m piggybacking on that, Joe. That was a great comment. That also means it’s not just about sales reps, it’s also about providing support to distributors, providing training support, marketing support, program support, etc., etc. Sometimes reimbursement support, market development support, allowing them to do a better job in the marketplace. All right? [Unidentified Analyst] for Jason Mills - Canaccord Adams: Just one more, just thinking about in terms of support as moved to the U.S. NanoKnife team, can you talk about the type of support that a center needs to get up and running and how long does it take, you know, from the time they decide to get a consult to they’re up to be able to be doing cases and you know, what’s the size of the team that’s running that now?

From the time we get a purchase order in hand, and of course that triggers the program, it’s typically about 30 to 45 days before the system is installed. We would send an engineer there to do the installation work. And then there would also be a clinical training period where we would either be training physicians on that machine or they would come to someplace else for training. And that would depend on the specific physicians. But I think generally speaking within 90 days of an installation, we would expect procedures to begin.

It’s more of a logistical issue than a training complexity issue. The actual manipulation of the NanoKnife electrodes is fairly easy trainable for the physicians we’re addressing here. There’s other sound or [inaudible] guided needle placement and they’re typically used to that through using our RF products or something along those lines. So these are very much existing customers, using similar technologies and similar support devices as they already have been doing. So the clinical training curve is fairly limited.

Your next question comes from Thomas Kouchoukos - Stifel Nicolaus & Company Inc. Thomas Kouchoukos - Stifel Nicolaus & Company Inc.: Following up on the IRE question in terms of kind of the trend and what we should see going forward, I know you know previously you guys had placed several boxes out in the field and just wanted to get a sense or the revenues that you recognized this period are those kind of conversions from the placements you had that decided to go ahead and buy the system from you or at least get into a commercial capacity with you?

In a case or two they are, but most of them are not. They’re brand new sites, if you will, long standing customers but new sites to IRE. Thomas Kouchoukos - Stifel Nicolaus & Company Inc.: Is there a backlog of any sort or is it too early to put a number on that?

A backlog of what? Prospective customers that are interested? Thomas Kouchoukos - Stifel Nicolaus & Company Inc.: Yes, and also the ones that you’ve already placed units with. Will they come around to a commercial capacity at some point or do you just keep those placements out there and generate disposable revenue?

Well, on the latter case, if the site doesn’t have an interest in going forward and makes some sort of a commitment to us, we will take the machines back. And it’s through those discussions that a couple of them have actually converted to these commercial sites. But we do also have a backlog of other potential customers that we hope to start to close in the third quarter, as well as some backlog of through the commitments that have been made to these two year purchases as well. So there’s a certain amount of revenue that we can anticipate from those sites also.

At some point down the road, all these historic customers if you want to qualify them like that will either be on the trials, on the clinical research trials, or will become commercial customers. That is the strategic direction. Thomas Kouchoukos - Stifel Nicolaus & Company Inc.: And then Johannes on benefits, you guys have had a couple of quarters of pretty nice sequential upticks. You know it still seems like there’s a lot of need for that type of product out in the field. At what point or what do you think you need to kind of crack the market open with this [audio impairment]?

Sorry, [audio impairment] the opening of your question there. The benefit? Thomas Kouchoukos - Stifel Nicolaus & Company Inc.: Yes, the benefit calendar and kind of what it takes to get the market. It seems like your growth is nice off of a small base, but what really breaks the market open for you?

Well, it is definitive or pivotal clinical trial. It’s a significant trial and you know this is 2010, we’ve commented on this before. I think this is a great example from that point of view. You’re asking physicians to use an additional device, lengthen the procedure, make it a little more expensive, and the first question is why would I do that? And that question can essentially at the end of the day only be answered by a definitive trial. Now rather than go into a big, randomized, pivotal trial giving the answer for eternity, we said let’s do a solid study, a single arm study, the provide registry. That is having a lot of traction, gets a lot of people enthusiastic to work with us and work with the device, along a base line and get a good story out, but eventually if you want to tap into the full potential of this device, potential market of this device, you probably have to do more than that. But that’s going to be several years out to be honest.

Your next question comes from Larry Haimovitch – HMTC.

It’s been probably many, many months now without a head of the Oncology division. To my knowledge you have not appointed anyone. I wonder if you might just update us on where that stands.

Larry, I commented on this before. We are looking for a very specific skill set to link the Oncology business and it is a specific profile, specific experience we’re looking for and we’ve got a long slate of candidates. We’re interviewing while we speak. The second thing is, it’s not like we have a burning platform here. You look at the operating results of the Oncology business, you look at the traction we’re starting to get on NanoKnife, on a day-to-day basis operationally this thing is managed pretty well by the interim general manager Rick Stark, whose daytime job is running Sales and Marketing, who does an outstanding job in just holding the team together, motivating the team on site. So it’s not like we have a burning platform from that point of view and we really want to make sure we get the right individual with the right skill set, right personality, that adds something to the mix rather than, you know, messing it up from that point of view. We did hire in the meantime, and it may be important to mention this as well, we did hire senior leadership when it comes to marketing product management, etc. So the training programs and some of the marketing programs you see coming out of those resources, those new people on the team as well. So again, not a burning platform, certainly doing our diligence in getting the right person and hopefully we cane make this happen in the not too distant future. Larry Haimovitch – HMTC: Johannes, I wonder if you could give us a little more color on the division. It obviously had a terrific quarter, even if you take away the NanoKnife which were all incremental. Where are you strong? Is it RF ablation? Is it the bead business? It’s clearly doing very, very well in the marketplace.

Yes, yes and yes, all three product lines now for the second quarter in a row are growing. So radio frequency ablation is growing, LC Bead obviously is growing, but also I want to give a little shout out to the [inaudible] team, who is really doing an outstanding job, arguably from a smaller footprint although it’s becoming quite significant as well. And looking at the markers in those three areas, it means we are gaining share and in the case of LC Bead frankly creating a market increasing the share, because we’ve got, you know, no meaningful competition in that segment. Larry Haimovitch – HMTC: And one question on the LC Beads, I think you still are being supplied by a third party if I recall correctly. That goes back to the biocompatibles deal, Johannes? Is there any thought of doing anything internally and having your own product line as well so you can capture greater gross margin there?

As we said before, the LC Beads is a great product despite having a below average gross margin because it’s quite profitable to us. We’re not carrying the burden off clinical development or R&D. The second thing I’d like to add to that is that this has been a tremendous successful relationship both with biocompatibles as well for ourselves and we like to believe that we can continue that relationship in the future.

Your next question comes from Jayson Bedford – Raymond James.

Just on the gross margin line, what drives gross margin expansion? What re-accelerates it? I’m guessing the pricing pressure’s going to continue, so I’m just wondering what other variable do you have to drive margin expansion?

The completion of various programs that bring product in house and the first of which is the TRT move from Fremont to Queensbury, and that one is you know probably 90% complete. And there are others that we’re doing right now as well, so that’s a fair amount of it. We also came into the year with higher than desired levels of inventories and we’ve been working through those inventory levels. So we anticipate a better level of factory utilization in the second half of the year and that, too, we don’t expect to run some of the adverse variances, manufacturing variances that we’ve had in the first quarter, don’t expect that to continue into the second. And then I think the other factor of course is the mix and the Beads has been the fastest growing product for a while. You know that may not necessarily be the case in the future and certainly as IRE rises as a percentage and becomes the meaningful amount of our sales, the margins on that are extremely high. So we can envision a day when the mix factors would be positive rather than negative factors in the analysis.

And someone mentioned earlier in the call corporate accounts, GPOs. How much of your business stems from that channel now?

I don’t have it available here. Honestly if we had it available I’m not sure we would break it out. But we do see a good chunk of growth, certainly in the Access business coming out of the corporate channels. So it’s increasingly important for us and we’d like a segment that we just added a resource to that department as well.

Thank you. And at this time I’d like to turn the conference back over to management for any closing comments.

Thank you, Mikayla, and thank you all for your interest in AngioDynamics. We’ll continue to provide updates on our progress and I’ll look forward to talking with you again during our third quarter fiscal 2010 conference call in early April, which by the way may be hosted from our new corporate office in Albany. Thank you all.